Limitations of antifungal prophylaxis in preventing invasive Candida surgical site infections after liver transplant surgery
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.01279-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von M Carugati und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, Duke University, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Liver Transplantation, Candidiasis, Invasive, Candidiasis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Invasive primary Candida surgical site infections (IP-SSIs) are a common complication of liver transplantation, and targeted antifungal prophylaxis is an efficient strategy to limit their occurrence. We performed a retrospective single-center cohort study among adult single liver transplant recipients at Duke University Hospital in the period between 1 January 2015 and 31 December 2020. The study aimed to determine the rate of Candida IP-SSI according to the peri-transplant antifungal prophylaxis received. Of 470 adult single liver transplant recipients, 53 (11.3%) received micafungin prophylaxis, 100 (21.3%) received fluconazole prophylaxis, and 317 (67.4%) did not receive systemic antifungal prophylaxis in the peri-transplant period. Ten Candida IP-SSIs occurred among 5 of 53 (9.4%) micafungin recipients, 1 of 100 (1.0%) fluconazole recipients, and 4 of 317 (1.3%) recipients who did not receive antifungal prophylaxis. Our study highlights the limitations of antifungal prophylaxis in preventing invasive Candida IP-SSI after liver transplant surgery. We hypothesize that pathogen, host, and pharmacokinetic-related factors contributed to the occurrence of Candida IP-SSI despite antifungal prophylaxis. Our study reinforces the need for a risk-based, multi-pronged approach to fungal prevention, including targeted antifungal administration in patients with risks for invasive candidiasis and close monitoring, especially among patients with surgically complex procedures, with timely control of surgical leaks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Infectious Diseases, Duke University, Durham, North Carolina, USA.
- Department of Medicine, Division of Gastroenterology, Duke University, Durham, North Carolina, USA.
- Department of Pharmacy, Duke University, Durham, North Carolina, USA.
- Department of Surgery, Division of Abdominal Transplant Surgery, Duke University, Durham, North Carolina, USA.
ORCID-Profile: M Carugati
Zitieren
APA
Carugati, M., Arif, S., Yarrington, M. E., King, L. Y., Harris, M., Evans, K., Barbas, A. S., Sudan, D. L., Perfect, J. R., Miller, R. A., & Alexander, B. D. (2024). Limitations of antifungal prophylaxis in preventing invasive Candida surgical site infections after liver transplant surgery. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01279-23
Vancouver
Carugati M, Arif S, Yarrington ME, King LY, Harris M, Evans K, et al. Limitations of antifungal prophylaxis in preventing invasive Candida surgical site infections after liver transplant surgery. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01279-23
BibTeX
@article{Carugati2024,
author = {Carugati, M and Arif, S and Yarrington, M E and King, L Y and Harris, M and Evans, K and Barbas, A S and Sudan, D L and Perfect, J R and Miller, R A and Alexander, B D},
title = {Limitations of antifungal prophylaxis in preventing invasive Candida surgical site infections after liver transplant surgery},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.01279-23}
}
EUVIMED